Trials / Active Not Recruiting
Active Not RecruitingNCT05990725
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Lebrikizumab | Lebrikizumab solution for injection administered subcutaneously. |
Timeline
- Start date
- 2023-11-20
- Primary completion
- 2025-06-23
- Completion
- 2025-06-23
- First posted
- 2023-08-14
- Last updated
- 2025-04-24
Locations
33 sites across 3 countries: Germany, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT05990725. Inclusion in this directory is not an endorsement.